Veto cells generated from memory t cells
AssigneeYeda Research and Development Co. Ltd.
InventorsYair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
Life of this patent
Estimating the term…
Loading patent…
AssigneeYeda Research and Development Co. Ltd.
InventorsYair REISNER, Noga OR-GEVA, Rotem GIDRON BUDOVSKY, Esther BACHAR-LUSTIG, Assaf LASK, Sivan KAGAN
Estimating the term…
A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, said cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, the method comprising:
(canceled)
A method of generating an isolated population of non-GvHD inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, said cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, the method comprising:
A method of generating an isolated population of non-GvHD inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, said cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation, the method comprising:
(canceled)
17-21. (canceled)
(canceled)
25-26. (canceled)
(canceled)
(canceled)
(canceled)
42-45. (canceled)
47-48. (canceled)
52-53. (canceled)
56-57. (canceled)
61-62. (canceled)
65-66. (canceled)
68-70. (canceled)
Dependencies are inferred from the claim text.